How some people resist a disease their genes made near-certain

Most of what genetics tells us about disease is a statement of risk: this variant raises the chance of that illness by so much. But scattered through the population are people whose genes said something close to a certainty, and for whom it did not happen anyway. They carry a mutation known to cause a serious disease, and they stay well. These individuals are among the most informative people in medicine, because whatever is protecting them is a mechanism that might one day be borrowed.

Why a "certain" mutation is not always certain

Geneticists describe this with the idea of penetrance — the proportion of people carrying a variant who actually develop the associated condition. Some mutations have low penetrance and only nudge risk. Others are close to fully penetrant, meaning almost everyone who inherits them develops the disease, usually at a predictable age.

Even in that second group, exceptions turn up. The reason is that no gene acts alone. Its effect is filtered through the rest of the genome, and a second variant elsewhere — a modifier or protective variant — can change the course of what the first one starts. It may alter a protein's shape, change how much of it is made, strengthen a repair pathway, or make a tissue more resilient to the damage being done to it.

This is why exceptional cases attract disproportionate scientific attention. In a common disease, thousands of small genetic contributions blur together. In a person who should have fallen ill and did not, the protective factor is doing something large enough to be visible.

A case in point: two carriers who stayed well

The clearest current example comes from an extended Colombian family carrying the PSEN1 E280A mutation, which causes autosomal-dominant Alzheimer's disease — carriers typically develop cognitive decline in their forties. Within that family, a small number of people have remained well far longer than expected.

A bioRxiv preprint posted on 3 August 2026 (10.64898/2026.08.03.742644) examines the brain tissue of two such carriers, both of whom resisted dementia for more than twenty years past the expected onset. One of them also carried a protective variant in the RELN gene, known as RELN-COLBOS.

Using single-nuclei and spatial transcriptomics — techniques that read gene activity cell by cell while preserving where each cell sat in the tissue — the authors compared the entorhinal cortex of these carriers against unprotected carriers, sporadic Alzheimer's cases and non-demented controls. They report cell populations in the protected man that they did not find in the comparison groups: RELN-positive inhibitory interneurons concentrated in cortical Layer I, and abundant ADAMTSL1-positive excitatory neurons in Layers II/III and Layer Va, alongside a raised neuronal density in that region.

Two cautions belong with that finding, and they are not formalities. The study is a preprint — it has not yet been peer reviewed, so it has not passed the independent scrutiny described in our explainer on peer review. And it describes two people. It is not a treatment, a trial or a therapy, and nothing in it tells anyone to expect a drug. What it offers is a candidate mechanism specific enough to be tested properly by others.

An exception is not a cure. It is a clue — and the whole reason to study a person the disease missed is to find out what it was that missed them.

From a rare individual to something useful

The path from an observation like this to medicine is long and mostly fails. A protective variant must first be shown to be genuinely responsible rather than coincidental, which needs more carriers, families or model systems. Then the mechanism must be worked out well enough to be imitated by a drug, an antibody or a gene therapy — because a protective variant is not something that can be handed to an adult patient directly.

The approach has worked before, which is why it is pursued. Rare individuals with loss-of-function variants in PCSK9 were found to have very low cholesterol and unusually low heart-disease risk; drugs that block the same protein now exist. That is the template: find the exception, identify the mechanism, reproduce the effect pharmacologically.

Why it matters for students and researchers

Protective-variant research sits at the meeting point of human genetics, neuroscience, molecular biology and drug discovery, and it inverts the usual question — instead of asking what causes disease, it asks what prevents it in someone who should have had it. The methods on display here are themselves worth attention: single-cell and spatial transcriptomics are reshaping how tissue is studied across cancer, immunology and neurodegeneration by showing not just which genes are active but exactly where. Reading such work critically also means reading it in order: preprint first, peer review later, replication after that. Following the peer-reviewed literature is how medical and life-science students and professionals distinguish a promising early signal from an established result.

Frequently asked questions

What is a protective genetic variant?

A protective genetic variant is a change in DNA that reduces the chance of developing a disease, or delays and softens it, even in someone who carries a mutation that would otherwise cause it. It works by modifying the biological pathway that the harmful mutation disrupts.

What does penetrance mean in genetics?

Penetrance is the proportion of people carrying a particular variant who actually develop the associated condition. A fully penetrant mutation causes disease in nearly everyone who inherits it, while a low-penetrance variant only raises risk. Exceptions to high penetrance often point to protective modifier variants.

What did the 2026 preprint on Alzheimer's resistance report?

It describes brain tissue from two carriers of the PSEN1 E280A mutation who avoided dementia for over twenty years beyond the expected onset, and reports unusual neuron populations in the entorhinal cortex of one carrier, who also had the RELN-COLBOS protective variant. It is a preprint that has not been peer reviewed, it covers two individuals, and it is not a treatment.

Why do researchers study people who do not get a disease they should have?

Because the protective factor in such a person is usually strong enough to identify, unlike the many small effects seen in common disease. If the mechanism can be understood, it may be reproduced with a drug — as happened when rare PCSK9 variants that lower cholesterol led to a class of cholesterol-lowering medicines.